Rich Rogers

DrRogers received his Ph.D. from the Johns Hopkins University in 2003.  His research focused on SUMO modification of transcription factors. As a post doc, DrRogers joined the Institute for Systems Biology.  At the ISB, DrRogers expanded his research on post translational modification by applying mass spectrometry to detect phosphoryatlation and other ubiquitin-like modifications in macrophages.  In 2012, DrRogers joined the Analytical Sciences group at Amgen.  At Amgen, DrRogers developed a mass spectrometry based multi-attribute method (MAM) for biotherapeutic characterization and release from QC.  At Just Biotherapeutics, DrRogers continued his work on MAM and started the MAM Consortium. DrRogers is currently exploring the uses of MAM for cell-based therapies at Juno Therapeutics in Seattle.


    Da Ren

Dr. Da Ren currently holds the position of Scientific Director in Process Development at Amgen, where he is responsible for global strategies for Multi-Attribute Method (MAM). Dr. Ren joined Amgen in 2004 and held multiple roles with increasing responsibility from analytical development to GMP release and stability testing. In 2015, he led the first in industry implementation of MAM in the GMP environment. He has more than 20 publications and patents applications during his tenure at Amgen. Prior to joining Amgen, Dr. Ren was a Senior Applications Chemist at Waters Corporation focusing on therapeutic protein characterization. He received his Ph.D. in Analytical Chemistry from the University of Akron in 2002.